Biomica has been recognized by IVC Research Center and Grove Ventures, as a Next-Gen Deep Tech startup in the Israeli healthcare ecosystem, together with other innovative startups
In The Media
Pharmabiotics 2020
Events
Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
Press Releases
The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials
Rehovot, Israel – January 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Chardan’s 2nd Annual Microbiome Medicines Summit
Events
JPMorgan Healthcare conference week
Events
4th Microbiome Movement – Drug Development Summit Europe 2020
Events
Biomica Reports Positive Preliminary Results in Animal Studies in its Immuno-Oncology Program
Press Releases
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127
Rehovot, Israel – November 12, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today positive preliminary results from recently completed animal studies in its immuno-oncology program,
Biomica To Collaborate with Weizmann Institute of Science to Develop A Selective Treatment Against Antibiotic Resistant Bacteria
Press Releases
The company has in-licensed IP and knowhow generated by Prof. Ada E. Yonath, Nobel Prize winner, who will advise Biomica on the program
Rehovot, Israel – October 23, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Biomica Initiates Pre-Clinical Studies in its Immuno-Oncology Program
Press Releases
Aims to augment current cancer therapies by altering patients’ gut microbiome to improve response
Rehovot, Israel – April 16, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Biomica and Weizmann Institute to develop a selective drug for resistant bacteria
In The Media